TEL AVIV, Israel, February 12, 2013 /PRNewswire/ --
Bioassociate has initiated coverage on Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP). The Initiation Report contains a detailed discussion of Oramed's business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks. The Initiation Report is available at: http://www.bioassociate.com/research-and-publications/publications/.
Dr. Ofir Levi , Bioassociate CEO: "Oramed is developing an orally ingestible capsule for the delivery of protein-based therapies with focus on treatment of diabetes. Oramed oral insulin, ORMD-0801, has demonstrated safety and efficacy in several clinical studies, and is scheduled to commence a phase 2 study under IND during 2013. Oramed recently raised $5M in a public offering and moved from being traded on the OTC Market to the NASDAQ. We anticipate that these events jointly with the advancement in the clinical development will increase investors' attention and trading volumes. For these reasons we, at Bioassociate, decide to initiate analysis coverage with a target price of $12.8 per share, which reflects an upside of 38%."
Bioassociate is an independent investment research firm specialized in the life-science sector. Bioassociate helps inform readers about small-mid cap life science companies without extensive analyst coverage. Bioassociate structures its teams with multidisciplinary members to conduct specific assignments. The Bioassociate team has industry experience as well as consulting and research track record, providing investors with in-depth scientific insights and their financial manifestation.
The research report described in this press release is not constructed
Copyright©2012 PR Newswire.
All rights reserved